PCVX Vaxcyte Inc
Price (delayed)
$73.06
Market cap
$9.41B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.8
Enterprise value
$9.09B
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious
Highlights
The EPS has increased by 17% from the previous quarter and by 8% YoY
Vaxcyte's equity has surged by 166% YoY but it has decreased by 3.3% QoQ
PCVX's quick ratio has surged by 68% year-on-year but it is down by 29% since the previous quarter
The debt has surged by 154% since the previous quarter and by 143% year-on-year
Key stats
What are the main financial stats of PCVX
Market
Valuations
Earnings
Shares outstanding
128.76M
Market cap
$9.41B
Enterprise value
$9.09B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$569.55M
Net income
-$463.93M
EBIT
-$463.93M
EBITDA
-$448.08M
Free cash flow
-$571.79M
Per share
Balance sheet
Liquidity
EPS
-$3.8
EPS diluted
-$3.8
Free cash flow per share
-$4.69
Book value per share
$26.52
Revenue per share
$0
TBVPS
$28.78
Total assets
$3.51B
Total liabilities
$205.5M
Debt
$71.11M
Equity
$3.31B
Working capital
$1.65B
Debt to equity
0.02
Current ratio
12.75
Quick ratio
12.46
Net debt/EBITDA
0.71
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-16.5%
Return on equity
-17.4%
Return on invested capital
-22.1%
Return on capital employed
-13.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCVX stock price
How has the Vaxcyte stock price performed over time
Intraday
-0.25%
1 week
-2.34%
1 month
-12.86%
1 year
-0.26%
YTD
-10.75%
QTD
-10.75%
Financial performance
How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$569.55M
Net income
-$463.93M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has decreased by 22% YoY but it has increased by 6% QoQ
The net income has contracted by 15% YoY but it has grown by 9% from the previous quarter
Growth
What is Vaxcyte's growth rate over time
Valuation
What is Vaxcyte stock price valuation
P/E
N/A
P/B
2.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 17% from the previous quarter and by 8% YoY
Vaxcyte's equity has surged by 166% YoY but it has decreased by 3.3% QoQ
The P/B is 29% lower than the 5-year quarterly average of 3.9 and 25% lower than the last 4 quarters average of 3.7
Efficiency
How efficient is Vaxcyte business performance
PCVX's ROIC has soared by 55% year-on-year and by 32% since the previous quarter
Vaxcyte's return on equity has increased by 46% YoY and by 26% QoQ
PCVX's ROA is up by 44% YoY and by 26% QoQ
Dividends
What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCVX.
Financial health
How did Vaxcyte financials performed over time
The company's total assets has surged by 149% YoY
Vaxcyte's current ratio has surged by 69% YoY but it has decreased by 29% QoQ
The debt is 98% smaller than the equity
Vaxcyte's equity has surged by 166% YoY but it has decreased by 3.3% QoQ
The debt has surged by 154% since the previous quarter and by 143% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.